Legislation to add sickle cell anemia as a qualifying condition for New Jersey’s medical marijuana program has unanimously cleared a second Senate committee, having already passed the full Assembly.
The Senate Budget and Appropriations Committee voted unanimously, 13 to 0, to advance the measure on Monday, sending it to the full Senate for consideration. The bill had already received unanimous approval earlier this session from the Senate Health, Human Services and Senior Citizens Committee, and it passed the full Assembly in May.
The proposal, Assembly Bill 913/Senate Bill 2392, would expressly allow patients diagnosed with sickle cell anemia to access medical marijuana through the state’s regulated program. If approved by the full Senate, it would be sent to Governor Phil Murphy for consideration.
Sickle cell anemia is a genetic blood disorder that can cause severe, recurring pain episodes and other serious complications. The condition disproportionately affects Black Americans, and supporters of the legislation argue that adding it to the list of qualifying conditions would give patients another option for managing chronic pain that is often difficult to treat with traditional medications alone.
New Jersey first enacted its medical marijuana law in 2010. Since then, the program has expanded to cover a wide range of conditions, including chronic pain, cancer, multiple sclerosis and post-traumatic stress disorder. Although adult-use marijuana sales are now legal in the state, medical patients continue to receive specific benefits not available in the recreational market, such as exemptions from the standard cannabis sales tax, higher possession and purchase limits, and broader access to certain products.
If enacted, the bill would formally recognize sickle cell anemia as a qualifying condition, ensuring patients living with the disorder have full access to New Jersey’s medical marijuana program.
Sponsored
